keyword
MENU ▼
Read by QxMD icon Read
search

Dronabinol

keyword
https://www.readbyqxmd.com/read/29134767/availability-and-approval-of-cannabis-based-medicines-for-chronic-pain-management-and-palliative-supportive-care-in-europe-a-survey-of-the-status-in-the-chapters-of-the-european-pain-federation
#1
N Krcevski-Skvarc, C Wells, W Häuser
BACKGROUND: There is considerable public and political interest in the use of cannabis products for medical purposes. METHODS: The task force of the European Pain Federation (EFIC) conducted a survey with its national chapters representatives on the status of approval of all types of cannabis-based medicines, the covering of costs and the availability of a position paper of a national medical association on the use of medical cannabis for chronic pain and for symptom control in palliative/supportive care...
November 13, 2017: European Journal of Pain: EJP
https://www.readbyqxmd.com/read/29121334/pharmacotherapy-of-apnea-by-cannabimimetic-enhancement-the-pace-clinical-trial-effects-of-dronabinol-in-obstructive-sleep-apnea
#2
David W Carley, Bharati Prasad, Kathryn J Reid, Roneil Malkani, Hryar Attarian, Sabra M Abbott, Boris Vern, Hui Xie, Chengbo Yuan, Phyllis Zee
Study Objectives: There remains an important and unmet need for fully effective and acceptable treatments in obstructive sleep apnea (OSA). At present, there are no approved drug treatments. Dronabinol has shown promise for OSA pharmacotherapy in a small dose-escalation pilot study. Here, we present initial findings of the Phase II PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial, a fully-blinded parallel groups, placebo-controlled randomized trial of dronabinol in patients with moderate or severe OSA...
November 7, 2017: Sleep
https://www.readbyqxmd.com/read/29073592/dronabinol-is-a-safe-long-term-treatment-option-for-neuropathic-pain-patients
#3
Sebastian Schimrigk, Martin Marziniak, Christine Neubauer, Eva Maria Kugler, Gudrun Werner, Dimitri Abramov-Sommariva
Treatment of neuropathic pain (NP) symptoms associated with multiple sclerosis (MS) is frequently insufficient. Yet, cannabis is still rarely offered for treatment of pain. This clinical trial aimed at showing the positive benefit-risk ratio of dronabinol. Two hundred forty MS patients with central NP entered a 16-weeks placebo-controlled phase-III study followed by a 32-weeks open-label period. One hundred patients continued therapy for overall up to 119 weeks. Primary endpoint was change of pain intensity on the 11-point Numerical Rating Scale over a 16-weeks treatment period...
October 26, 2017: European Neurology
https://www.readbyqxmd.com/read/29066964/using-functional-near-infrared-spectroscopy-to-measure-effects-of-delta-9-tetrahydrocannabinol-on-prefrontal-activity-and-working-memory-in-cannabis-users
#4
Hasan O Keles, Milena Radoman, Gladys N Pachas, A Eden Evins, Jodi M Gilman
Intoxication from cannabis impairs cognitive performance, in part due to the effects of Δ9-tetrahydrocannabinol (THC, the primary psychoactive compound in cannabis) on prefrontal cortex (PFC) function. However, a relationship between impairment in cognitive functioning with THC administration and THC-induced change in hemodynamic response has not been demonstrated. We explored the feasibility of using functional near-infrared spectroscopy (fNIRS) to examine the functional changes of the human PFC associated with cannabis intoxication and cognitive impairment...
2017: Frontiers in Human Neuroscience
https://www.readbyqxmd.com/read/29035934/dextrometorphan-paroxetine-but-not-dronabinol-effective-for-treatment-resistant-aggression-and-agitation-in-an-elderly-patient-with-lewy-body-dementia
#5
Robert Wilhelm, Björn Ahl, Ion-George Anghelescu
No abstract text is available yet for this article.
October 13, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29017688/cannabinoids-in-pain-management-and-palliative-medicine
#6
Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke
BACKGROUND: There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. METHODS: We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, and Medline...
September 22, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28934522/effects-of-cannabinoid-agonists-and-antagonists-on-sleep-and-breathing-in-sprague-dawley-rats
#7
Michael W Calik, David W Carley
Study Objectives: There are no pharmacological treatments for obstructive sleep apnea syndrome, but dronabinol showed promise in a small pilot study. In anesthetized rats, dronabinol attenuates reflex apnea via activation of cannabinoid (CB) receptors located on vagal afferents; an effect blocked by cannabinoid type 1 (CB1) and/or type 2 (CB2) receptor antagonists. Here, using a natural model of central sleep apnea, we examine the effects of dronabinol, alone and in combination with selective antagonists in conscious rats chronically instrumented to stage sleep and measure cessation of breathing...
September 1, 2017: Sleep
https://www.readbyqxmd.com/read/28796166/speechlessness-in-gilles-de-la-tourette-syndrome-cannabis-based-medicines-improve-severe-vocal-blocking-tics-in-two-patients
#8
Ewgeni Jakubovski, Kirsten Müller-Vahl
We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 × 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated...
August 10, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28780725/a-review-of-oral-cannabinoids-and-medical-marijuana-for-the-treatment-of-chemotherapy-induced-nausea-and-vomiting-a-focus-on-pharmacokinetic-variability-and-pharmacodynamics
#9
REVIEW
Melissa E Badowski
PURPOSE: Oral cannabinoids (i.e., dronabinol, nabilone) containing the active component of marijuana, delta(Δ)9-tetrahydrocannabinol (THC), are available for the treatment of chemotherapy-induced nausea and vomiting (CINV) in patients with cancer who have failed to adequately respond to conventional antiemetic therapy. The aim of this article is to provide an overview of the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of oral cannabinoids for patients with CINV...
August 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28641496/guanfacine-attenuates-adverse-effects-of-dronabinol-thc-on-working-memory-in-adolescent-onset-heavy-cannabis-users-a-pilot-study
#10
David S Mathai, Manuela Holst, Christopher Rodgman, Colin N Haile, Jake Keller, Mariyah Z Hussain, Thomas R Kosten, Thomas F Newton, Christopher D Verrico
The cannabinoid-1 receptor (CB1R) agonist Δ9-tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, adversely effects working memory performance in humans. The α2A-adrenoceptor (AR) agonist guanfacine improves working memory performance in humans. The authors aimed to determine the effects of short-term (6 days) treatment with guanfacine on adverse cognitive effects produced by THC. Employing a double-blind, placebo-controlled crossover design, the cognitive, subjective, and cardiovascular effects produced by oral THC (20 mg) administration were determined twice in the same cannabis users: once after treatment with placebo and once after treatment with guanfacine (3 mg/day)...
June 23, 2017: Journal of Neuropsychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/28564576/the-endocannabinoid-system-as-a-target-for-addiction-treatment-trials-and-tribulations
#11
REVIEW
Matthew E Sloan, Joshua L Gowin, Vijay A Ramchandani, Yasmin L Hurd, Bernard Le Foll
Addiction remains a major public health concern, and while pharmacotherapies can be effective, clinicians are limited by the paucity of existing interventions. Endocannabinoid signaling is involved in reward and addiction, which raises the possibility that drugs targeting this system could be used to treat substance use disorders. This review discusses findings from randomized controlled trials evaluating cannabinergic medications for addiction. Current evidence suggests that pharmacotherapies containing delta-9-tetrahydrocannabinol, such as dronabinol and nabiximols, are effective for cannabis withdrawal...
September 15, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/28537982/selective-cannabinoids-for-chronic-neuropathic-pain-a-systematic-review-and-meta-analysis
#12
REVIEW
Howard Meng, Bradley Johnston, Marina Englesakis, Dwight E Moulin, Anuj Bhatia
BACKGROUND: There is a lack of consensus on the role of selective cannabinoids for the treatment of neuropathic pain (NP). Guidelines from national and international pain societies have provided contradictory recommendations. The primary objective of this systematic review and meta-analysis (SR-MA) was to determine the analgesic efficacy and safety of selective cannabinoids compared to conventional management or placebo for chronic NP. METHODS: We reviewed randomized controlled trials that compared selective cannabinoids (dronabinol, nabilone, nabiximols) with conventional treatments (eg, pharmacotherapy, physical therapy, or a combination of these) or placebo in patients with chronic NP because patients with NP may be on any of these therapies or none if all standard treatments have failed to provide analgesia and or if these treatments have been associated with adverse effects...
November 2017: Anesthesia and Analgesia
https://www.readbyqxmd.com/read/28452845/dronabinol-induced-acute-altered-mental-status-in-an-elderly-patient
#13
Ankur Sinha, Prabhsimranjot Singh, Yizhak Kupfer
No abstract text is available yet for this article.
April 25, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28355049/schedules-of-controlled-substances-placement-of-fda-approved-products-of-oral-solutions-containing-dronabinol-delta-9-transtetrahydrocannabinol-delta-9-thc-in-schedule-ii-interim-final-rule-with-request-for-comments
#14
(no author information available yet)
On July 1, 2016, the U.S. Food and Drug Administration (FDA) approved a new drug application for Syndros, a drug product consisting of dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] oral solution. Thereafter, the Department of Health and Human Services (HHS) provided the Drug Enforcement Administration (DEA) with a scheduling recommendation that would result in Syndros (and other oral solutions containing dronabinol) being placed in schedule II of the Controlled Substances Act (CSA). In accordance with the CSA, as revised by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing FDA-approved products of oral solutions containing dronabinol in schedule II of the CSA...
March 23, 2017: Federal Register
https://www.readbyqxmd.com/read/28349316/cannabis-cannabinoids-and-sleep-a-review-of-the-literature
#15
REVIEW
Kimberly A Babson, James Sottile, Danielle Morabito
PURPOSE OF REVIEW: The current review aims to summarize the state of research on cannabis and sleep up to 2014 and to review in detail the literature on cannabis and specific sleep disorders from 2014 to the time of publication. RECENT FINDINGS: Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term...
April 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/28281107/cannabis-for-pain-and-headaches-primer
#16
REVIEW
Philip S Kim, Michael A Fishman
PURPOSE OF REVIEW: Marijuana has been used both medicinally and recreationally since ancient times and interest in its compounds for pain relief has increased in recent years. The identification of our own intrinsic, endocannabinoid system has laid the foundation for further research. RECENT FINDINGS: Synthetic cannabinoids are being developed and synthesized from the marijuana plant such as dronabinol and nabilone. The US Food and Drug Administration approved the use of dronabinol and nabilone for chemotherapy-associated nausea and vomiting and HIV (Human Immunodeficiency Virus) wasting...
April 2017: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/28276820/cannabinoids-for-treating-inflammatory-bowel-diseases-where-are-we-and-where-do-we-go
#17
REVIEW
Carina Hasenoehrl, Martin Storr, Rudolf Schicho
Fifty years after the discovery of Δ(9)-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects...
April 2017: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28161834/cannabinoid-receptors-in-regulating-the-gi-tract-experimental-evidence-and-therapeutic-relevance
#18
REVIEW
Ulrike Taschler, Carina Hasenoehrl, Martin Storr, Rudolf Schicho
Cannabinoid receptors are fundamentally involved in all aspects of intestinal physiology, such as motility, secretion, and epithelial barrier function. They are part of a broader entity, the so-called endocannabinoid system which also includes their endocannabinoid ligands and the ligands' synthesizing/degrading enzymes. The system has a strong impact on the pathophysiology of the gastrointestinal tract and is believed to maintain homeostasis in the gut by controlling hypercontractility and by promoting regeneration after injury...
2017: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/28156443/a-single-dose-comparative-bioavailability-study-of-dronabinol-oral-solution-versus-dronabinol-capsules-in-healthy-volunteers
#19
Neha Parikh, William G Kramer, Varun Khurana, Santosh Vetticaden
198 Background: The capsule formulation of dronabinol, a pharmaceutical tetrahydrocannabinol (THC), is approved for anorexia associated with weight loss in patients with AIDS and for cancer chemotherapy-associated nausea/vomiting in patients with inadequate response to conventional antiemetics. A new oral formulation (i.e., dronabinol solution) was evaluated in a bioequivalence study versus currently marketed dronabinol capsules. METHODS: In an open-label, 2-treatment, 2-sequence, 4-period, single-dose crossover study, healthy volunteers were randomized to receive 1 of 2 treatment sequences (T-R-T-R or R-T-R-T; T = dronabinol 4...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156442/effect-of-food-on-the-pharmacokinetics-of-dronabinol-oral-solution-versus-dronabinol-capsules-in-healthy-volunteers
#20
D Alexander Oh, Neha Parikh, Varun Khurana, Santosh Vetticaden
199 Background: Dronabinol, a pharmaceutical tetrahydrocannabinol (THC), capsule is approved for anorexia associated with weight loss in patients with AIDS and for cancer chemotherapy-induced nausea/vomiting in patients with inadequate response to conventional antiemetic therapy. Food effects on absorption and bioavailability of a new dronabinol oral solution was compared with marketed capsules. METHODS: In an open-label, single-dose, 3-period crossover study, healthy volunteers were randomized to receive dronabinol oral solution 4...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
36767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"